Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28719400 | 0.90 | MMP2 (0.56) | ALDH1A1SMN1; SMN2KDM4ELMNAPKM | |
| SCHEMBL18966907 | 0.89 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2KDM4ELMNAPKM | |
| SCHEMBL4521936 | 0.86 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2KDM4ELMNAPKM | |
| SCHEMBL8851631 | 0.86 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2KDM4ELMNAPKM | |
| SCHEMBL20327817 | 0.84 | ALDH1A1 (0.62) | ALDH1A1LMNAKMT2ANPSR1HTT | |
| SCHEMBL5649673 | 0.82 | KMT2A (0.57) | ALDH1A1SMN1; SMN2KDM4ELMNAPKM | |
| SCHEMBL26787768 | 0.82 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2LMNAPKMKMT2A | |
| SCHEMBL3704958 | 0.82 | CA12 (0.71) | ALDH1A1KMT2ANAMPTHTT | |
| SCHEMBL27896976 | 0.82 | HTT (0.72) | ALDH1A1KDM4EKMT2ANPSR1HTT | |
| SCHEMBL3153289 | 0.82 | SIGMAR1 (0.59) | ALDH1A1KMT2ANAMPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-3097076-B1 | NOVEL CYP-EICOSANOID DERIVATIVES | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-05-08 | — | — | EP | disclosed |
| CN-106146358-B | Method for synthesizing amino- (N-alkyl) benzene sulfonamide | 南京理工大学 | 2018-01-23 | — | — | CN | disclosed |
| US-9676760-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676760-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9598435-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598435-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160347744-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160096846-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9193694-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20140135317-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8586732-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130184255-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2013-01-10 | — | — | US | disclosed |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2013-01-10 | — | — | US | disclosed |
| EP-1443041-A1 | 5-AMIDINO-2-HYDROXYBENZENESULFONAMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATES IN THE PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184255-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | ALDH1A1 2454/4885SMN1; SMN2 1420/4885KDM4E 1140/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ALDH1A1 4236/4885SMN1; SMN2 2633/4885KDM4E 4338/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | ALDH1A1 4236/4885SMN1; SMN2 2633/4885KDM4E 4338/4885 |
| US-20130012492-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | ALDH1A1 2454/4885SMN1; SMN2 1420/4885KDM4E 1140/4885 |
| US-20160347744-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | ALDH1A1 2454/4885SMN1; SMN2 1420/4885KDM4E 1140/4885 |
| US-20140135317-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | ALDH1A1 2454/4885SMN1; SMN2 1420/4885KDM4E 1140/4885 |
| US-20160096846-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNJ4 | ALDH1A1 2454/4885SMN1; SMN2 1420/4885KDM4E 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.